These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16164221)

  • 21. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T; Nakashima T; Hiroshi N; Penninger JM
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo.
    Jimi E; Aoki K; Saito H; D'Acquisto F; May MJ; Nakamura I; Sudo T; Kojima T; Okamoto F; Fukushima H; Okabe K; Ohya K; Ghosh S
    Nat Med; 2004 Jun; 10(6):617-24. PubMed ID: 15156202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A tumor necrosis factor-alpha antagonist inhibits inflammatory bone resorption induced by Porphyromonas gingivalis infection in mice.
    Suzuki Y; Aoki K; Saito H; Umeda M; Nitta H; Baron R; Ohya K
    J Periodontal Res; 2006 Apr; 41(2):81-91. PubMed ID: 16499710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
    Woo JT; Nakagawa H; Krecic AM; Nagai K; Hamilton AD; Sebti SM; Stern PH
    Biochem Pharmacol; 2005 Jan; 69(1):87-95. PubMed ID: 15588717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis.
    Wada T; Nakashima T; Oliveira-dos-Santos AJ; Gasser J; Hara H; Schett G; Penninger JM
    Nat Med; 2005 Apr; 11(4):394-9. PubMed ID: 15750601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
    Aoki K; Saito H; Itzstein C; Ishiguro M; Shibata T; Blanque R; Mian AH; Takahashi M; Suzuki Y; Yoshimatsu M; Yamaguchi A; Deprez P; Mollat P; Murali R; Ohya K; Horne WC; Baron R
    J Clin Invest; 2006 Jun; 116(6):1525-34. PubMed ID: 16680194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand.
    Xu J; Tan JW; Huang L; Gao XH; Laird R; Liu D; Wysocki S; Zheng MH
    J Bone Miner Res; 2000 Nov; 15(11):2178-86. PubMed ID: 11092398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.
    Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Yano K; Morinaga T; Higashio K
    Biochem Biophys Res Commun; 1998 Dec; 253(2):395-400. PubMed ID: 9878548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1).
    Kwak HB; Jin HM; Ha H; Kang MJ; Lee SB; Kim HH; Lee ZH
    Biochem Biophys Res Commun; 2005 May; 330(4):1080-6. PubMed ID: 15823554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
    Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
    Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [RANKL/RANK signal transduction].
    Takayanagi H
    Nihon Rinsho; 2005 Sep; 63(9):1502-4. PubMed ID: 16164202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.